CompletedNCT04533529
A Study of Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Participants With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant and Long-term Safety Extension Treatment With Seltorexant
Medication studyAges 18–74Multiple countriesDepression
Understand this study
Who was this study for?
Listed age limits: 18 years to 74 years.
- Listed locations
- Anaheim and 121 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateStarted: September 16, 2020
- Recruitment status
- Completed
- Enrollment listed in the registry
- 588
- Sponsor
- Janssen Research & Development, LLC
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States, Brazil, Bulgaria, ...
- Age range
- From 18 Years to 74 Years
- Official registry ID
- NCT04533529
- Official title
Show the full official title
A Multicenter, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled, Study to Evaluate the Efficacy and Safety of Seltorexant 20 mg as Adjunctive Therapy to Antidepressants in Adult and Elderly Patients With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant Therapy and an Open-labeled Long-term Safety Extension Treatment With Seltorexant
Get this study by email
Recruitment & locations
CompletedAnaheim, United States · Cerritos, United States · Irvine, United States
97 more locations
- La Habra, United States
- Lemon Grove, United States
- Los Angeles, United States
- Montclair, United States
- Oakland, United States
- Oceanside, United States
- Santa Ana, United States
- Temecula, United States
- Cromwell, United States
- Farmington, United States
- Gainesville, United States
- Jacksonville, United States
- Miami, United States
- Miami Springs, United States
- North Bay Village, United States
- Orlando, United States
- Elgin, United States
- Joliet, United States
- Naperville, United States
- Oak Brook, United States
- Springfield, United States
- Shreveport, United States
- Watertown, United States
- Bloomfield Hills, United States
- Saint Charles, United States
- St Louis, United States
- Lincoln, United States
- Las Vegas, United States
- Berlin, United States
- Jamaica, United States
- Mount Kisco, United States
- Avon Lake, United States
- Columbus, United States
- Mason, United States
- Oklahoma City, United States
- Allentown, United States
- Philadelphia, United States
- Dallas, United States
- Fort Worth, United States
- Houston, United States
- Clinton, United States
- Rutland, United States
- Belo Horizonte, Brazil
- Brasília, Brazil
- Curitiba, Brazil
- Fortaleza, Brazil
- Passo Fundo, Brazil
- Rio de Janeiro, Brazil
- São Paulo, Brazil
- Burgas, Bulgaria
- Cherven Bryag, Bulgaria
- Kardzhali, Bulgaria
- Plovdiv, Bulgaria
- Slivnitsa, Bulgaria
- Sofia, Bulgaria
- Targovishte, Bulgaria
- Vratsa, Bulgaria
- Barranquilla, Colombia
- Bello, Colombia
- Bogotá, Colombia
- Medellín, Colombia
- Pereira, Colombia
- Kladno, Czechia
- Kutná Hora, Czechia
- Pilsen, Czechia
- Prague, Czechia
- Monterrey, Mexico
- Nuevo León, Mexico
- San Luis Potosí City, Mexico
- Saint Petersburg, Russia
- Stavropol, Russia
- Yaroslavl, Russia
- Bloemfontein, South Africa
- Cape Town, South Africa
- Krugersdorp, South Africa
- Mamelodi East, South Africa
- Pretoria, South Africa
- Strand, South Africa
- Barcelona, Spain
- Bilbao, Spain
- Madrid, Spain
- Oviedo, Spain
- Pamplona, Spain
- Sabadell, Spain
- Salamanca, Spain
- Zamora, Spain
- Halmstad, Sweden
- Helsingborg, Sweden
- Lund, Sweden
- Malmö, Sweden
- Skövde, Sweden
- Stockholm, Sweden
- Keelung, Taiwan
- Taipei, Taiwan
- Taoyuan County, Taiwan
- Czechia
- Russia
Questions about this study
Who is behind this study?
The study sponsor is Janssen Research & Development, LLC.
Did this study involve medication?
Yes. The study involved medication, including Seltorexant and Placebo.
Who was this study for?
Listed age limits: 18 years to 74 years.
